Pathways to the best fit of triptans for migraine patients

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Variability in drug response is a major barrier to the successful treatment of migraine, and most treatments are only optimal in a subset of patients. Although triptans provide the best therapeutic option for the treatment of acute migraine, it has not previously been possible to predict how well patients will respond to a specific triptan or whether they will experience unpleasant adverse events. Hence, it has been difficult for physicians to match individual patients with the most suitable agent to treat their migraine pain. Intrapatient variability has been associated with polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters and drug targets. Pharmacogenetics provides the possibility of tailoring the therapeutic approach to individual patients, in order to maximize treatment efficacy while minimizing the potential for unwanted side-effects. This review demonstrates how almotriptan may overcome genetically determined responses by utilizing diverse metabolic pathways to provide therapeutic benefit to many migraineurs.

Original languageEnglish
Pages (from-to)21-27
Number of pages7
JournalCephalalgia
Volume28
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Sep 2008

Fingerprint

Tryptamines
Migraine Disorders
Pharmaceutical Preparations
Therapeutics
Pharmacogenetics
Metabolic Networks and Pathways
Physicians
Pain
Enzymes
Genes

Keywords

  • Almotriptan
  • Metabolism
  • Migraine
  • Pharmacogenomics
  • Triptans

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Pathways to the best fit of triptans for migraine patients. / Buzzi, M. G.

In: Cephalalgia, Vol. 28, No. SUPPL. 2, 09.2008, p. 21-27.

Research output: Contribution to journalArticle

@article{b70c911b89294295a46e3e155ee0b330,
title = "Pathways to the best fit of triptans for migraine patients",
abstract = "Variability in drug response is a major barrier to the successful treatment of migraine, and most treatments are only optimal in a subset of patients. Although triptans provide the best therapeutic option for the treatment of acute migraine, it has not previously been possible to predict how well patients will respond to a specific triptan or whether they will experience unpleasant adverse events. Hence, it has been difficult for physicians to match individual patients with the most suitable agent to treat their migraine pain. Intrapatient variability has been associated with polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters and drug targets. Pharmacogenetics provides the possibility of tailoring the therapeutic approach to individual patients, in order to maximize treatment efficacy while minimizing the potential for unwanted side-effects. This review demonstrates how almotriptan may overcome genetically determined responses by utilizing diverse metabolic pathways to provide therapeutic benefit to many migraineurs.",
keywords = "Almotriptan, Metabolism, Migraine, Pharmacogenomics, Triptans",
author = "Buzzi, {M. G.}",
year = "2008",
month = "9",
doi = "10.1111/j.1468-2982.2008.01687.x",
language = "English",
volume = "28",
pages = "21--27",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Pathways to the best fit of triptans for migraine patients

AU - Buzzi, M. G.

PY - 2008/9

Y1 - 2008/9

N2 - Variability in drug response is a major barrier to the successful treatment of migraine, and most treatments are only optimal in a subset of patients. Although triptans provide the best therapeutic option for the treatment of acute migraine, it has not previously been possible to predict how well patients will respond to a specific triptan or whether they will experience unpleasant adverse events. Hence, it has been difficult for physicians to match individual patients with the most suitable agent to treat their migraine pain. Intrapatient variability has been associated with polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters and drug targets. Pharmacogenetics provides the possibility of tailoring the therapeutic approach to individual patients, in order to maximize treatment efficacy while minimizing the potential for unwanted side-effects. This review demonstrates how almotriptan may overcome genetically determined responses by utilizing diverse metabolic pathways to provide therapeutic benefit to many migraineurs.

AB - Variability in drug response is a major barrier to the successful treatment of migraine, and most treatments are only optimal in a subset of patients. Although triptans provide the best therapeutic option for the treatment of acute migraine, it has not previously been possible to predict how well patients will respond to a specific triptan or whether they will experience unpleasant adverse events. Hence, it has been difficult for physicians to match individual patients with the most suitable agent to treat their migraine pain. Intrapatient variability has been associated with polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters and drug targets. Pharmacogenetics provides the possibility of tailoring the therapeutic approach to individual patients, in order to maximize treatment efficacy while minimizing the potential for unwanted side-effects. This review demonstrates how almotriptan may overcome genetically determined responses by utilizing diverse metabolic pathways to provide therapeutic benefit to many migraineurs.

KW - Almotriptan

KW - Metabolism

KW - Migraine

KW - Pharmacogenomics

KW - Triptans

UR - http://www.scopus.com/inward/record.url?scp=48249100185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249100185&partnerID=8YFLogxK

U2 - 10.1111/j.1468-2982.2008.01687.x

DO - 10.1111/j.1468-2982.2008.01687.x

M3 - Article

C2 - 18715329

AN - SCOPUS:48249100185

VL - 28

SP - 21

EP - 27

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - SUPPL. 2

ER -